U.S. patent application number 14/260099 was filed with the patent office on 2014-08-21 for molecular motor.
This patent application is currently assigned to The USA, as represented by the Secretary, Dep. of Health and Human Services. The applicant listed for this patent is The USA, as represented by the Secretary, Dept of Health and Human Services, The USA, as represented by the Secretary, Dept of Health and Human Services. Invention is credited to Ilya G. Lyakhov, Thomas D. Schneider.
Application Number | 20140234948 14/260099 |
Document ID | / |
Family ID | 22519827 |
Filed Date | 2014-08-21 |
United States Patent
Application |
20140234948 |
Kind Code |
A1 |
Schneider; Thomas D. ; et
al. |
August 21, 2014 |
MOLECULAR MOTOR
Abstract
A molecular motor in which multiple concentric cylinders (or
nested cones) rotate around a common longitudinal axis. Opposing
complementary surfaces of the cylinders or cones are coated with
complementary motor protein pairs (such as actin and myosin). The
actin and myosin interact with one another in the presence of ATP
to rotate the cylinders or cones relative to one another, and this
rotational energy is harnessed to produce work. The concentration
of ATP and the number of nested cylinders or cones can be used to
control the rotational speed of the motor. The length of the
cylinders can also be used to control the power generated by the
motor. In another embodiment, the molecular motor includes at least
two annular substrates wherein one annular substrate is coated with
a first motor protein and the other annular substrate is coated
with a second motor protein. The first and second motor proteins
interact with each other to move the second annular relative to the
first annular substrate.
Inventors: |
Schneider; Thomas D.;
(Frederick, MD) ; Lyakhov; Ilya G.; (Frederick,
MD) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The USA, as represented by the Secretary, Dept of Health and Human
Services |
Bethesda |
MD |
US |
|
|
Assignee: |
The USA, as represented by the
Secretary, Dep. of Health and Human Services
Bethesda
MD
|
Family ID: |
22519827 |
Appl. No.: |
14/260099 |
Filed: |
April 23, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13306774 |
Nov 29, 2011 |
|
|
|
14260099 |
|
|
|
|
12011239 |
Jan 24, 2008 |
8086432 |
|
|
13306774 |
|
|
|
|
10061377 |
Feb 1, 2002 |
7349834 |
|
|
12011239 |
|
|
|
|
PCT/US00/20095 |
Jul 24, 2000 |
|
|
|
10061377 |
|
|
|
|
60146975 |
Aug 3, 1999 |
|
|
|
Current U.S.
Class: |
435/283.1 ;
29/434 |
Current CPC
Class: |
B82B 1/00 20130101; C12M
99/00 20130101; Y10S 977/729 20130101; C07K 14/4716 20130101; B82B
3/00 20130101; Y10T 156/10 20150115; H02N 11/006 20130101; B82Y
40/00 20130101; Y10T 29/4984 20150115; B82Y 30/00 20130101 |
Class at
Publication: |
435/283.1 ;
29/434 |
International
Class: |
C12M 1/00 20060101
C12M001/00 |
Claims
1. A molecular motor comprising: a stationary substrate defining a
first planar surface coated with a first motor molecule; a terminal
annular substrate defining a first planar surface coated with a
second motor molecule; and at least one intermediate annular
substrate interposed between the stationary substrate and the
terminal annular substrate, the intermediate annular substrate
defining a first planar surface coated with the second motor
molecule and an obverse second surface coated with the first motor
molecule; wherein the stationary substrate, terminal annular
substrate, and intermediate annular substrate are arranged such
that each substrate surface coated with the first motor molecule is
adjacent to a substrate surface coated with the second motor
molecule.
2. The molecular motor of claim 1, wherein the first motor molecule
comprises myosin and the second motor molecule comprises actin,
which can interact with the myosin to move the intermediate annular
substrate and the terminal annular substrate.
3. The molecular motor of claim 1, wherein the intermediate annular
substrate and the terminal annular substrate each comprise at least
two concentric rings.
4. The molecular motor of claim 2, further comprising a driven
member rotatable by the interaction between the intermediate
annular substrate and the terminal annular substrate.
5. The molecular motor of claim 4, wherein the driven member is an
internal shaft or cylinder in the motor.
6. The molecular moor of claim 1, wherein the motor has a
longitudinal axis of rotation, the first motor molecule and the
second motor molecule is each directionally aligned with respect to
each other such that orientation of the second motor molecule
directs movement of the terminal annular substrate, the second
motor molecule being directionally aligned substantially
perpendicular to the longitudinal axis of rotation.
7. The molecular motor of claim 1, wherein the first and second
motor molecules are proteins.
8. A molecular motor comprising: a first layer of a plurality of
concentric first rings, each first ring defining a planar surface
coated with a first motor molecule; and a second layer of a
plurality of concentric second rings, each second ring defining a
planar surface coated with a second motor molecule that interacts
with the first motor molecule to move the second rings relative to
the first rings.
9. The molecular motor of claim 8, wherein the concentric first
rings and the concentric second rings are rotatable about a
longitudinal axis, and the first layer is axially adjacent to the
second layer along the longitudinal axis.
10. The molecular motor according to claim 9, further comprising a
first gap between each adjacent first ring of the first layer and a
second gap between each adjacent second ring of the second layer,
wherein the first layer and the second layer are arranged relative
to each other such that each first gap is radially offset from each
second gap.
11. The molecular motor according to claim 8, further comprising at
least one additional layer of a plurality of concentric third
rings, each third ring defining a first planar surface coated with
the first motor molecule and a second planar surface coated with
the second motor molecule, wherein the first layer, second layer,
and additional layer are arranged such that each planar substrate
surface coated with the first motor molecule is adjacent to a
planar substrate surface coated with the second motor molecule.
12. The molecular motor of claim 8, wherein the first and second
motor molecules are proteins.
13. A method of making a molecular motor, comprising: providing a
first annular substrate defining a planar surface; providing a
second annular substrate defining a planar surface; adhering a
first motor molecule to the planar surface of the first annular
substrate; adhering a second motor molecule to the planar surface
of the second annular substrate; and positioning the first annular
substrate relative to the second annular substrate so that the
first motor molecule can interact with the second motor molecule to
move the first annular substrate relative to the second annular
substrate.
14. The method of claim 13, wherein the first and second motor
molecules are proteins.
15. A molecular motor comprising: first two dimensional arrays of a
first motor molecule; and second two dimensional arrays of a second
motor molecule that interact with the first motor molecule to move
directionally relatively to the first array; wherein the first and
second arrays of motor molecules are in sufficiently close contact
to interact and move the second array relative to the first array
and there are multiple nested first and second arrays that interact
with one another to directionally move the first and second arrays
relative to one another.
16. The molecular motor of claim 13, wherein the first and second
motor molecules are proteins.
Description
PRIORITY CLAIM
[0001] This is a divisional of U.S. patent application Ser. No.
13/306,774, filed Nov. 29, 2011, which is a divisional of U.S.
patent application Ser. No. 12/011,239, filed Jan. 24, 2008, issued
as U.S. Pat. No. 8,086,432, which is a divisional of U.S. patent
application Ser. No. 10/061,377, filed Feb. 1, 2002, issued as U.S.
Pat. No. 7,349,834, which is a continuation-in-part application,
and claims benefit of PCT Application PCT/US00/20925 filed Jul. 31,
2000, which was published in English under PCT Article 21(2), and
designating the U.S., which claims the benefit of U.S. Provisional
Application No. 60/146,975 filed Aug. 3, 1999, all of which are
incorporated herein by reference in their entireties.
FIELD OF THE DISCLOSURE
[0002] This disclosure relates to molecular motors, and
particularly such motors that are powered by proteins.
BACKGROUND OF THE DISCLOSURE
[0003] One of the fundamental properties of biological organisms is
the ability to move, or to at least transport cellular components,
even on a molecular scale. The biological structure that permits
macroscopic movement in animals is muscle, which can be either
striated (skeletal), smooth, or cardiac. The molecular structure
and function of muscle has been the subject of scientific
fascination and research for over a century. As early as the 1840s,
William Bowman had suggested that striations in skeletal muscle
represented bands of intracellular material with differing
refractive indices. These intracellular materials were eventually
identified as actin and myosin.
[0004] The contractile unit in skeletal muscle is known as a
myofibril, which consists of a series of Z-disks to which are
attached thin filaments of actin. The Z-disks divide each myofibril
into repeating units called sarcomeres, and within each sarcomere
is a thick filament of myosin which has heads that can form
crossbridges to the actin. In the presence of ATP, the myosin heads
undergo a conformational change that causes the cross bridges to
link to the actin, and the myosin heads move the actin filaments
relative to the myosin filaments. This movement brings the Z-disks
closer together, which on a macroscopic level contracts (shortens)
the muscle, and implements musculoskeletal function. Although
cardiac and smooth muscle differ in their cellular architecture
from skeletal muscle, they too rely on the interaction of myosin
and actin to contract.
[0005] The myosin molecule consists of six polypeptide subunits:
two identical heavy chains with a molecular weight of about 200,000
kDa each, and four light chains of about 20 kDa each. In electron
micrographs, purified myosin looks like a long thin rod containing
two globular heads protruding at one end. This two-headed type of
myosin is called myosin II to distinguish it from the smaller,
single headed myosin I molecule (having a shorter tail) that is
involved in cytoplasmic movements in some nonmuscle cells. The
functions of portions of the myosin molecule have been investigated
by using the protease trypsin to cleave the myosin II molecule into
two fragments called light meromyosin (a coiled tail portion) and
heavy meromysin (which contains the globular heads of the molecule,
and a portion of the coiled tail). The function of actin and
myosin, and their molecular structure, are more fully described in
Kendrew, The Encyclopedia of Molecular Biology, 1994, pages
688-691; and Kleinsmith and Kish, Principles of Cell and Molecular
Biology, second edition, 1995, chapter 13, which are incorporated
by reference.
[0006] A variety of motor proteins other than actin and myosin are
also known.
[0007] The motor protein kinesin, for example, was discovered in
1985 in squid axoplasm. Vale et al., Cell 42:39-50, 1985. Kinesin
is just one member of a very large family of motor proteins. Endow,
Trends Biochem. Sci. 16:221-225, 1991; Goldstein, Trends Cell Biol.
1:93, 1991; Stewart et al., Proc. Natl. Acad. Sci. USA
88:8470-8474, 1991. Another such motor protein is dynein. Li et
al., J. Cell Biol. 126:1475-1493, 1994. Kinesin, dynein, and
related proteins move along microtubules, whereas myosin moves
along actin filaments. Like myosin, kinesin is activated by
ATP.
[0008] Kinesin is composed of two heavy chains (each about 120 kDa)
and two light chains (each about 60 kDa). The kinesin heavy chains
include three structural domains: (a) an amino-terminal head
domain, which contains the sites for ATP and microtubule binding
and for motor activity; (b) a middle or stalk domain, which may
form an .alpha.-helical coiled coil that entwines two heavy chains
to form a dimer; and (c) a carboxyl-terminal domain, which probably
forms a globular tail that interacts with the light chains and
possibly with vesicles and organelles. Kinesin and kinesin-like
proteins are all related by sequence similarity within an
approximately 340-amino acid region of the head domain, but outside
of this conserved region they show no sequence similarity.
[0009] Purified motor proteins are capable of generating movement
even outside biological organisms. The motility activity of
purified kinesin on microtubules has, for example, been
demonstrated in vitro. Vale al., Cell 42:39-50, 1985. Full-length
kinesin heavy chain and several types of truncated kinesin heavy
chain molecules produced in E. coli are also capable of generating
in vitro microtubule motility. Yang et al., Science 249:42-47,
1990; Stewart et al., Proc. Natl. Acad. Sci. USA 90:5209-5213,
1993. The kinesin motor domain has also been shown to retain motor
activity in vitro after genetic fusion to several other proteins
including spectrin (Yang et al.), glutathione S-transferase
(Stewart et al.), and biotin carboxyl carrier protein (Berliner,
269 J. Biol. Chem. 269:8610-8615, 1994).
[0010] Similarly, methods have been developed for purification or
recombinant production and manipulation of motor proteins, and
methods of attaching actin to non-biological substrates are also
known. Ishima et al., Cell 92:161-171, 1998. Microtubules can be
routinely reassembled in vitro from tubulin purified from bovine
brains. The nucleation, assembly, and disassembly reactions of
microtubules have been well characterized. Cassimeris et al.,
Bioessays 7:149-154, 1987. More recently, recombinant tubulin has
been produced in yeast. Davis et al., Biochemistry 32:8823-8835,
1993.
[0011] Efforts have been made in the past to harness the molecular
activity of motor proteins for useful work outside of biological
organisms. U.S. Pat. No. 5,830,659, for example, disclosed a system
for purifying a molecule of interest from a mixture by aligning
microtubules in a separation channel leading out of a liquid
reservoir. A kinesin-ligand complex was then added to the liquid
reservoir, in the presence of ATP, and the ligand was selected to
bind to the molecule of interest in the liquid. When the kinesin
came into contact with the microtubules in the channel, the
kinesin-ligand (and its bound molecule of interest) were
transported through the channel into a collection reservoir, so
that the molecule of interest was purified away from the
mixture.
[0012] Another motor protein device is shown in Japanese patent
5-44298 (JP 5-44298), which describes a pump for moving liquid.
Actin is mounted onto a surface of a container in the direction of
the desired flow, and meromyosin and ATP are supplied in the
liquid. The interaction of the meromyosin and actin "push" the
liquid in the direction of flow.
[0013] Nicolau et al., SPIE 3241:36-46, 1997 discusses constructing
a molecular motor or engine using actin and myosin. A rotatable
gear is mounted on a stationary base, and the gear has teeth to
which arms of actin are attached. Using lithographic techniques of
the type used in semiconductor fabrication, a track of myosin is
laid down along the peripheral edge of the stationary base so that
the arms of actin on the rotatable gear can adhere to the track,
and pull the teeth of the gear along the myosin track when ATP is
supplied to the system. This arrangement is apparently designed to
rotate the gear, and impart rotation to a driven gear that engages
the driving gear. However, the myosin track in such a device would
be crushed by the teeth of the gear as the gear rotates, or would
jam.
[0014] Moreover, precise microlithographic positioning of the actin
and myosin molecules would be difficult, and perhaps unfeasible,
and alignment of the actin arms along the myosin track could not be
maintained. It also does not appear that the molecular motor could
be scaled up to macroscopic proportions, nor is it clear how the
power or speed of the device could be controlled.
[0015] It is a goal of certain embodiments of the present
disclosure to solve some of the problems of prior approaches by
devising a molecular motor that is more easily fabricated, and may
if desired be scaled up to macroscopic proportions.
[0016] It is also a goal of some embodiments to devise such a
molecular motor in which power and speed of the motor can be more
conveniently controlled.
SUMMARY OF THE DISCLOSURE
[0017] The molecular motor of the present disclosure includes first
and second complementary two dimensional arrays of a motor protein,
for example adhered to a substrate surface. The first and second
arrays of motor proteins are in sufficiently close contact to
interact and directionally move one array (and its attached
substrate) relative to the other. This action in turn moves a
driven member, such as a shaft or gear, to convert the movement
into useful power that can produce work.
[0018] In some embodiments, there are multiple layers of nested
(for example concentric) complementary first and second arrays that
interact with one another to directionally move the first and
second arrays relative to one another. The arrays may be adhered to
a curved surface, such as, for example, a continuous curved surface
of rotation having a longitudinal axis and an internal radius (for
example a cylinder or cone). Alternatively, the arrays may be
adhered to a planar surface of an annular substrate, such as, for
example, a disc or a ring. According to a further variation, the
arrays may be adhered to a flexible continuous loop surface that
can transform between a curved surface and a planar surface as the
loop rotates around internal radii. Multiple concentric cylinders,
nested cones, concentric rings, or nested loops (which rotate
around a common central longitudinal axis) can form a series of
complementary surfaces to which the arrays are adhered.
[0019] In particular embodiments, the motor proteins are actin and
myosin, and the motor includes a source of ATP for activating the
myosin to operate the motor. The ATP can be supplied in a liquid
that flows longitudinally through the rotatable surfaces on which
the arrays are adhered, or the ATP containing liquid may be infused
through perforations in surfaces on which the arrays are disposed,
to allow permeation of an ATP containing liquid through the
surfaces to the motor proteins.
[0020] When actin/myosin are the motor proteins, the actin may be
applied directionally to a substrate surface and the myosin is
applied to a complementary or opposing substrate surface. The
actin-coated surface and the myosin-coated surface are in
sufficiently close contact that the motor proteins interact to move
the surfaces relative to one another, in a direction determined by
the directional application of the actin to its surface.
[0021] An array of the first motor protein may be coated on a first
curved or planar surface, and an array of the second motor protein
may be coated on a second complementary curved or planar surface,
such that the first and second motor proteins interact to move the
second surface in a predetermined direction relative to the first
surface. In an illustrative example, one of the arrays is coated on
an outer surface of a cylinder, shaft or cone, and another of the
arrays is coated on an inner surface of a surrounding structure
having a complementary shape that substantially conforms to a shape
of the outer surface of the cylinder, shaft or cone. The
directional movement of the second surface moves a driver, such as
an internal shaft or cylinder in the motor. Alternatively, the
driver may be an outer curved surface of the motor (such as an
outer surface of an outermost cylinder of the motor). The driven
member can take a variety of forms, such as a rotating shaft, a
propeller, a wheel, a lever-arm, a gear system, or a pulley
system.
[0022] An advantage of the disclosed motor is that the arrays can
be of a preselected dimension that provides a preselected power
output of the motor. For example, the length of a cylinder on which
the complementary arrays are coated can be selected to vary the
power output. Alternatively, a speed of rotation of the motor can
be varied by preselecting the number of multiple nested
complementary arrays or the number of stacked, array-coated annular
substrates. Alternatively, the speed of rotation can be controlled
by altering the concentration of ATP to which the motor proteins
are exposed. As the concentration of ATP increases, the speed of
the motor will increase up to a maximum speed, at which all the
motor proteins are maximally functioning.
[0023] In a more specific embodiment, the molecular motor includes
a series of concentric tubes or hollow cones, wherein each of the
tubes or hollow cones has an outer surface and an inner surface. A
first motor protein array (such as an actin array) is attached in a
continuous ring of a selected width around the outer surface of
each of the tubes or cones, and a second motor protein (such as
myosin) is attached in a continuous complementary array of a
corresponding width around the inner surface of each of the tubes
or cones.
[0024] In a further embodiment, the molecular motor includes a
first annular substrate defining at least one planar surface coated
with a first motor protein and a second annular substrate defining
at least one planar surface coated with a second motor protein that
interacts with the first motor protein to move the second annular
substrate relative to the first annular substrate. The annular
substrate may be a thin disc or a ring. For example, the motor may
include at least two layers of a plurality of concentric rings. One
variant of the annular substrate embodiment includes a stationary
substrate, a terminal annular substrate, and at least one
intermediate annular substrate interposed between the stationary
substrate and the terminal annular substrate. The stationary
substrate, terminal annular substrate, and intermediate annular
substrate are arranged such that each planar surface coated with a
first motor protein is adjacent to a planar surface coated with a
second motor protein. A second variant of the annular substrate
embodiment includes a stationary member affixed to the first
annular substrate and a rotatable member affixed to the second
annular substrate wherein the first motor protein can interact with
the second motor protein to move the second annular substrate
relative to the first annular substrate and consequently rotate the
rotatable member.
[0025] An additional molecular motor embodiment includes at least
one continuous loop of a flexible substrate that defines at least
two turning radii and at least one surface that is coated with a
first motor protein. Rotation loci members are disposed at the
turning radii and at least one of the rotation loci members defines
a surface coated with a second motor protein. The interaction of
the first motor protein and the second motor protein moves the
flexible substrate relative to at least one of the rotation loci
members.
[0026] The motor proteins can be attached to the surfaces in a
variety of ways. The actin, for example, can be expressed by
recombinant techniques as a fusion protein with a histidine tag,
which is then attached to a nickel-coated surface. Alternatively,
the actin can be expressed with an S-tag which binds to an
S-protein coated surface, or with a streptavidin tag which binds to
biotin on a substrate surface. In another specific, non-limiting
example, gelsolin is used to attach the actin to a surface (e.g.
see Suzuki et al., Biophys. J. 70:401-408, 1996).
[0027] In particular embodiments, the first motor protein (for
example actin) is directionally attached on the outer surface of a
rotatable cylinder or cone in an array that extends both
longitudinally along and circumferentially around the tube or cone,
and the second motor protein (such as myosin) extends both
longitudinally along and circumferentially around the tube or cone
in a complementary array of similar size.
[0028] The disclosure also describes a method of making a molecular
motor, by providing a first continuous curved surface which rotates
around a longitudinal axis, and a second curved surface which
rotates around the longitudinal axis, and is complementary in shape
to the first surface. Another method of making a molecular motor
contemplates providing a first annular substrate defining a planar
surface and a second annular substrate defining a planar surface,
adhering a first motor protein to the planar surface of the first
annular substrate and a second motor protein to the planar surface
of the second annular substrate, and positioning the first annular
substrate relative to the second annular substrate so that the
first motor protein can interact with the second motor protein to
move the first annular substrate relative to the second annular
substrate.
[0029] In the disclosed methods, a first motor protein (such as
actin) is directionally adhered to the first surface, and a second
motor protein (such as myosin) is adhered to the second surface,
such that the first and second motor proteins interact to move the
first and second surfaces relative to one another. In particular
embodiments, the actin is adhered to the surface with a tag (for
example a recombinantly expressed tag such as histidine, an S-tag
or streptavidin) that interacts with a component of the first
surface. The actin may be directionally applied to the planar or
first curved surfaces by rotating the planar or curved surface in
an actin containing solution.
[0030] In certain embodiments, the motor proteins can be portions
of actin and myosin that are able to function to move the surfaces
relative to one another. For example, heavy meromyosin or myosin I
can be used instead of myosin II. In other embodiments, the motor
proteins are microtubules and kinesin, or functional fragments
thereof that are sufficient to move the surfaces. The kinesin can
be, for example, the N-terminal 410 amino acid residues of
kinesin.
[0031] The motor of the present disclosure may be a micromachined
device constructed on a micrometer-scale, but the motor can also be
constructed on a much larger scale by coating larger surfaces with
the motor proteins, which can be purified from biological tissues
(such as muscle) or produced in large quantities using recombinant
techniques.
[0032] The molecular motors of the present disclosure are believed
to operate much more efficiently than conventional engines that use
large temperature differentials or magnetic fields to create rotary
motion with energetic efficiencies less than about 35%. The Carnot
efficiency of an internal combustion engine is 56%, but other
losses reduce the efficiency to about 25%. Many such engines also
depend on fossil fuels that create air pollution and may induce
global warming as a consequence of the combustion of such
fuels.
[0033] Muscles use contractile or motor molecules to create
macroscopic motion with efficiencies near 70%, and the molecular
motors of the present disclosure can use similarly efficient
systems to create useful energy. This can be accomplished while
producing substantially no pollution, because sugar (or ATP itself)
could be used to fuel the motors, and the waste products (ADP and
Pi) are biologically useful or biodegradable. In addition, the
isothermal conditions under which the motor operates imply low
materials stress, and easier construction and maintenance.
[0034] The biologically compatible nature of these devices also
makes them suitable for medical applications. Biologically based
engines can use sugar in the blood (via substrate level
phosphorylation glycolysis) as fuel, to replace neuromuscular
function lost to diseases such as myasthenia gravis or muscular
dystrophy. Alternatively, the motor can be used to perform the
mechanical functions of a prosthetic implant.
[0035] The foregoing and other objects, features, and advantages of
the disclosed molecular motor will become more apparent from the
following detailed description of several embodiments which
proceeds with reference to the accompanying figures.
BRIEF DESCRIPTION OF THE FIGURES
[0036] FIG. 1 is a schematic illustration of one embodiment of the
molecular motor, in which actin is directionally applied on an
outer surface of a solid internal cylinder, myosin is coated on an
internal surface of a surrounding complementary hollow cylinder,
and rotation of the internal cylinder drives a rotary gear.
Portions of the outer cylinder are broken away to illustrate that
the arrays of actin and myosin extend along the length of the
device.
[0037] FIG. 2 is a schematic illustration similar to FIG. 1, but
wherein the surfaces are on cones instead of cylinders.
[0038] FIG. 3A is a side elevational and FIG. 3B is a cross
sectional schematic end view of an alternative embodiment of the
disclosure in which the layer of actin surrounds the myosin layer,
the inner cylinder is fixed to a stationary bracket, and rotation
of the outer cylinder rotates a propeller.
[0039] FIGS. 4A through 4E are successive schematic views
illustrating a conventional view of the interaction of actin and a
single myosin head, to demonstrate how an actin coated surface is
moved by the myosin.
[0040] FIGS. 5A through 5E are schematic end views of cylinders
similar to those shown in FIG. 1, showing a subset of myosin heads
that change conformation substantially in concert to move the
internal actin coated cylinder of the motor. Other myosin heads
(not shown) are randomly moving through different stages of the
conformational changes, without necessarily moving in concert, but
only a single subset of myosin heads have been shown for purposes
of explanation.
[0041] FIG. 6 is a schematic side view of an alternative embodiment
of the motor having multiple, nested, concentric complementary
cylinders on which the actin and myosin are coated.
[0042] FIG. 7A is a schematic end perspective view of two
interengaging complementary cylinders that can be interengaged to
assemble a molecular motor of the present disclosure.
[0043] FIG. 7B is a side view of the complementary cylinders of
FIG. 4, illustrating the differing outer diameters of the two
cylinders.
[0044] FIG. 8 is a schematic illustration of one embodiment of the
molecular motor, in which ATP is supplied from a reservoir.
Separate feed lines are used to supply the ATP to the motor. Each
feed line (ATP.sub.1, ATP.sub.2, and ATP.sub.3) has a control
switch or valve (designated "X" on the ATP.sub.1, ATP.sub.2, and
ATP.sub.3 feed lines). In one embodiment, the control valves are
separately controlled.
[0045] FIG. 9 is a schematic illustration of another embodiment of
the molecular motor, which includes separate units in series. In
this embodiment, segments of a molecular motor, separated by
impermeable barriers, are connected in series by a shaft. The
barrier is designed to prevent diffusion between the molecular
motor units. In this embodiment, ATP is supplied from a reservoir
through separate feed lines (designated ATP.sub.1, ATP.sub.2,
ATP.sub.3 and ATP.sub.4). Each feed line (ATP.sub.1, ATP.sub.2,
ATP.sub.3 and ATP.sub.4) has a separately controlled switch or
valve (designated "X" on ATP.sub.1, ATP.sub.2, ATP.sub.3 and
ATP.sub.4 feed lines).
[0046] FIG. 10 is a schematic illustration of another embodiment of
the molecular motor wherein actin and myosin, respectively, are
coated on opposing axially aligned annular substrate surfaces.
[0047] FIG. 11 is a cross-section side view of a further embodiment
of a molecular motor that includes discs coated with actin and
myosin.
[0048] FIGS. 12A and 12B are each plan views of disc embodiments
that could be used in the molecular motor shown in FIG. 10 or 11.
FIG. 12A shows actin directionally applied on one surface of the
disc. FIG. 12B shows myosin applied on one surface of the disc.
[0049] FIG. 13 is a schematic view of a molecular motor embodiment
similar to that shown in FIG. 10 or 11 wherein rings are
substituted for the discs. FIG. 13 includes a plan view of the
rings and a side view of multiple ring layers wherein the spatial
correspondence between the two views is illustrated by dashed
lines.
[0050] FIG. 14 is a cross-section side view of another variant of
the molecular motor depicted in FIG. 1 or FIG. 2.
[0051] FIG. 15 is a cross-section side view of a further variant of
the molecular motor depicted in FIG. 1 or FIG. 2.
DETAILED DESCRIPTION OF SEVERAL EMBODIMENTS
Definitions
[0052] The following definitions and methods are provided to better
describe the present disclosure and to guide those of ordinary
skill in the art in the practice of the present disclosure.
Definitions of common terms may also be found in Rieger et al.,
Glossary of Genetics: Classical and Molecular, 5th edition,
Springer-Verlag: New York, 1991; and Lewin, Genes V, Oxford
University Press: New York, 1994. The standard one and three letter
nomenclature for amino acid residues is used (such as H or His for
Histidine).
[0053] Additional definitions of terms commonly used in molecular
genetics can be found in Benjamin Lewin, Genes V published by
Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al
(eds.), The Encyclopedia of Molecular Biology, published by
Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A.
Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive
Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN
1-56081-569-8).
[0054] As used in this specification and the appended claims, the
singular forms "a," "an," and "the" include plural referents unless
the context clearly dictates otherwise. Thus, for example,
reference to a motor comprising "a cylinder" includes a system
containing one or more cylinders, and reference to "a motor
protein" includes reference to one or more motor proteins.
[0055] Micromachining, micromachined, and similar terms refer to
the processes used to create micrometer-sized structures with
primarily mechanical functions on substrates such as glass,
silicon, silica, or a photoreactive polymer-coated chip.
[0056] Motor protein means a protein that transduces chemical
energy into mechanical force and motion. Such motor proteins often
exist in complementary pairs, such as actin and myosin, or kinesin
and microtubules. Particular disclosed motor proteins are
actin/myosin and kinesin/microtubles. The motor proteins can be
used in any form that is capable of transducing the chemical energy
(such as the energy of ATP) into mechanical force and motion. Hence
variants or fragments of the molecules can be used, such as myosin
I or myosin II, or heavy meromyosin (although light meromyosin
would not be suitable because it lacks the heads which change
conformation to transduce the chemical energy). Similarly, variant
or mutant forms of the motor proteins, such as variant actin or
myosin (for example proteins in which conservative amino acid
substitutions have been made) are also included, as long as they
retain the motor activity. Actin is a directionally oriented
molecule, that (when applied directionally to a substrate) helps
direct myosin along a substrate in a direction determined by the
orientation of the actin molecules on the surface. Actin and myosin
have been well studied, and mutations that affect their function
have been reported in the scientific literature to provide guidance
about making mutants. See, for example, J. Cell. Biol.,
134:895-909, 1996; J. Biol. Chem. 269:18773-18780, 1994; and
Bioessays 19:561-569, 1997.
[0057] The motor proteins may also include kinesin and related
proteins, such as ncd, as disclosed in Endow et al., Nature
345:81-83, 1990, that are highly processive, i.e. which do not
readily detach from directional microtubule tracks to which they
are coupled. Once such highly processive motor proteins attach to a
microtubule, there is a relatively high likelihood that they will
move for many micrometers along the microtubule before becoming
detached. Kinesin moves toward the plus-end of microtubules,
whereas ncd moves toward the minus-end of microtubules. Hence, like
actin, the microtubules can be applied directionally to a substrate
to pre-select a direction of rotation of the surfaces relative to
one another. The direction of rotation can be varied, depending on
the complementary motor protein which is selected (for example,
kinesin or ncd).
[0058] The motor proteins also include species variations, and
various sequence polymorphisms that exist, wherein amino acid
substitutions in the protein sequence do not affect the essential
functions of the protein.
[0059] Coupling of a motor protein to the surfaces of the rotatable
cylinders, cones, discs, rings, or loops of the motor can be
accomplished by any method known in the art, as long as the motor
activity of the protein is preserved. An example of a method of
expressing actin as a fusion protein that is then coupled to a
substrate is given in Example 4, in which a fusion protein is
expressed by recombinant DNA technology. Briefly, a gene encoding a
motor protein is operably linked to a gene encoding a selected tag
(such as poly-His or streptavidin) to construct a gene fusion,
which is then expressed in a suitable expression system such as E.
coli or yeast to produce the fusion protein. Coupling of the motor
protein to the substrate can also be accomplished by other methods,
such as chemical coupling or purified proteins.
[0060] Effective amount means an amount of a source of chemical
energy, such as ATP, sufficient to permit a selected motor protein
to generate mechanical force.
[0061] ATP means adenosine triphosphate, a mononucleotide that
stores chemical energy that is used by motor proteins, such as
myosin and kinesin, for producing movement. ADP refers to adenosine
diphosphosphate.
[0062] GTP means guanosine 5'-triphosphate, a mononucleotide that
stores chemical energy.
[0063] cDNA (complementary DNA): a piece of DNA lacking internal,
non-coding segments (introns) and regulatory sequences which
determine transcription. cDNA is synthesized in the laboratory by
reverse transcription from messenger RNA extracted from cells.
[0064] Deletion: the removal of a sequence of DNA, the regions on
either side being joined together.
[0065] Fuel source means a molecule that stores chemical energy. In
one embodiment, the energy molecule is a nucleoside triphosphate
(NTP), such as ATP or GTP.
[0066] Motor protein gene: a gene (DNA sequence) encoding a motor
protein (such as actin or myosin). A mutation of the gene (to
produce variant forms of the motor protein) may include nucleotide
sequence changes, additions or deletions. The term "gene" is
understood to include the various sequence polymorphisms and
allelic variations that exist within the population. This term
relates primarily to an isolated coding sequence, but can also
include some or all of the flanking regulatory elements and/or
intron sequences.
[0067] NTP means a nucleoside 5'-triphosphate, e.g. ATP or GTP.
[0068] Isolated: requires that the material be removed from its
original environment. For example, a naturally occurring DNA or
protein molecule present in a living animal is not isolated, but
the same DNA or protein molecule, separated from some or all of the
coexisting materials in the natural system, is isolated.
[0069] Operably linked: a first nucleic acid sequence is operably
linked with a second nucleic acid sequence when the first nucleic
acid sequence is placed in a functional relationship with the
second nucleic acid sequence. For instance, a promoter is operably
linked to a coding sequence if the promoter affects the
transcription or expression of the coding sequence. Generally,
operably linked DNA sequences are contiguous and, where necessary
to join two protein coding regions, in the same reading frame.
[0070] ORF: open reading frame. Contains a series of nucleotide
triplets (codons) coding for amino acids without any termination
codons. These sequences are usually translatable into protein.
[0071] PCR: polymerase chain reaction. Describes a technique in
which cycles of denaturation, annealing with primer, and then
extension with DNA polymerase are used to amplify the number of
copies of a target DNA sequence.
[0072] Purified: the term "purified" does not require absolute
purity; rather, it is intended as a relative term. Thus, for
example, a purified protein preparation is one in which the protein
referred to is more pure than the protein in its natural
environment within a cell. The term "substantially pure" refers to
a purified protein having a purity of at least about 75%, for
example 85%, 95% or 98%.
[0073] Recombinant: a recombinant nucleic acid is one that has a
sequence that is not naturally occurring or has a sequence that is
made by an artificial combination of two otherwise separated
segments of sequence. This artificial combination is often
accomplished by chemical synthesis or, more commonly, by the
artificial manipulation of isolated segments of nucleic acids,
e.g., by genetic engineering techniques.
[0074] Sequence identity: the similarity between two nucleic acid
sequences, or two amino acid sequences, is expressed in terms of
the similarity between the sequences, otherwise referred to as
sequence identity. Sequence identity is frequently measured in
terms of percentage identity (or similarity or homology); the
higher the percentage, the more similar are the two sequences.
[0075] Methods of alignment of sequences for comparison are
well-known in the art. Various programs and alignment algorithms
are described in: Smith and Waterman, Adv. Appl. Math. 2:482, 1981;
Needleman and Wunsch, J. Mol. Bio. 48:443, 1970; Pearson and
Lipman, Methods in Mol. Biol. 24: 307-31, 1988; Higgins and Sharp,
Gene 73:237-44, 1988; Higgins and Sharp, CABIOS 5:151-3, 1989;
Corpet et al., Nuc. Acids Res. 16:10881-90, 1988; Huang et al.,
Comp. Appl. BioSci. 8:155-65, 1992; and Pearson et al., Meth. Mol.
Biol. 24:307-31, 1994.
[0076] The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul
et al., J. Mol. Biol. 215:403-10, 1990) is available from several
sources, including the National Center for Biological Information
(NCBI, Bethesda, Md.) and on the Internet, for use in connection
with the sequence analysis programs blastp, blastn, blastx, tblastn
and tblastx. It can be accessed at the NCBI web site. A description
of how to determine sequence identity using this program is
available at the NCBI web site.
[0077] Variants or homologs of the motor protein are typically
characterized by possession of at least 70% sequence identity
counted over the full length alignment with the disclosed amino
acid sequence using the NCBI Blast 2.0, gapped blastp set to
default parameters. Such homologous peptides will more preferably
possess at least 75%, more preferably at least 80% and still more
preferably at least 90%, 95% or 98% sequence identity determined by
this method. Sequence identity can be determined, in one instance,
by aligning sequences and determining how many differences there
are in the aligned sequence, and expressing these differences as a
percentage. When less than the entire sequence is being compared
for sequence identity, homologs will possess at least 75% and more
preferably at least 85% and more preferably still at least 90%, 95%
or 98% sequence identity over short windows of 10-20 amino acids.
Methods for determining sequence identity over sequence windows are
described at the NCBI web site. For comparisons of nucleic acid
sequences of less than about 150 nucleic acids, the Blast 2
sequences function is employed using the default 0 BLOSUM62 matrix
set to default parameters, (OPEN GAP 5, extension gap 2). Nucleic
acid sequences with even greater similarity to the reference
sequences will show increasing percentage identities when assessed
by this method, such as at least 45%, 50%, 70%, 80%, 85%, 90%, 95%
or 98% sequence identity.
[0078] The present disclosure provides not only the peptide
homologs that are described above, but also nucleic acid molecules
that encode such homologs.
[0079] Transformed: a transformed cell is a cell into which has
been introduced a nucleic acid molecule by molecular biology
techniques. As used herein, the term transformation encompasses all
techniques by which a nucleic acid molecule might be introduced
into such a cell, including transfection with viral vectors,
transformation with plasmid vectors, and introduction of naked DNA
by electroporation, lipofection, and particle gun acceleration.
[0080] Vector: a nucleic acid molecule is introduced into a host
cell, thereby producing a transformed host cell. A vector may
include nucleic acid sequences that permit it to replicate in a
host cell, such as an origin of replication. A vector may also
include one or more selectable marker genes and other genetic
elements known in the art.
PARTICULAR EMBODIMENTS
Example 1
[0081] A particular embodiment of the molecular motor 10 is
illustrated in FIG. 1, in which the motor is shown to include a
solid inner cylinder 12 and a hollow outer cylinder 14 that is of
slightly larger diameter than inner cylinder 12. An extension 16 of
inner cylinder 12 projects from motor 10, and carries a driver in
the form of a toothed gear 18. The teeth on gear 18 mesh with the
teeth of a larger gear 20, so that rotation of gear 18 in the
direction of arrow 22 will rotate gear 20 in the direction of arrow
24.
[0082] Although the dimensions of motor 10 are not critical, the
inner cylinder 12 may have a diameter of 20 microns to 1 meter, for
example 1 cm, while the outer cylinder 14 may have a diameter of 40
microns to 1 meter, for example 1 cm. A clearance distance between
an outer surface of cylinder 12 and an inner surface of cylinder 14
is, for example, in the range of 20 to 30 microns.
[0083] Referring again to FIG. 1, a layer of actin 30 is
directionally applied to the outer surface of cylinder 12, with the
directional orientation shown as arrows in the drawing. As
described in greater detail in Example 4, the actin protein may be
expressed with a histidine tag (for example His-6) that binds to
nickel. The actin is polymerized to form actin fibers by bringing a
Mg.sup.2+ concentration to physiological levels, as described in
Korn et al., Science 238:638-644, 1987. A cylinder with a nickel
outer surface is placed into the actin-His-6 fiber solution so that
the fibers attach to the surface of the cylinder. The cylinder may
then be placed in a normal (non-His-6) actin solution (for example
by adding normal actin to the solution) to extend the actin fibers
to a length beyond their persistence length (at which point the
actin has no particular direction). More actin-His-6 is then added
to the solution, so that the ends of the actin cables have a His
tag, and the cylinder is rotated in the actin solution to
directionally orient the actin cables, and allow the His tags at
the free end of the actin cables to attach to the nickel containing
surface of the cylinder 12.
[0084] The directionality of the actin cables is schematically
illustrated in FIG. 1 by arrows 32 in the actin layer 30. As shown
by the cut away portion of cylinder 14 in FIG. 1, the coating of
actin covers the curved surface of inner cylinder 12 substantially
along its length, for substantially coating that surface of the
cylinder. In particular embodiments, the actin is present in a
substantially continuous layer around the circumference of the
cylinder 12, for substantially the entire length of the cylinder
inside outer cylinder 14. The thickness of the actin layer may be,
for example, 1 to 10 molecules thick, and in a particular disclosed
embodiment is one molecule thick.
[0085] The myosin (for example in the form of myosin I, myosin II,
or heavy meromyosin, or variants thereof) can be adhered to the
inner surface of cylinder 14, before actin coated cylinder 12 is
placed inside cylinder 14. The myosin is adhered to the inner
surface of cylinder 14 by adhesion, or by the techniques shown in
Finer et al., Nature 368:113-119, 1994, and Ishijima et al., Cell
92:161-171, 1998, as well as Ishijima et al, Biophys. J.
70:383-400, 1996 (incorporated by reference), in which myosin was
purified and bound to a glass surface. When heavy meromyosin (HMM)
is used as the motor protein, the technique used in Suzuki et al.,
Biophys. J. 72:1997-2001, 1997 (incorporated by reference) can be
used. In this method, HMM (0.1 mg/ml) in an assay buffer solution
(40 mM KCl, 3 mM MgCl2, 2 mM EGTA, 10 mM dithiothreitol, and 20 mM
HEPES at pH 7.8) is dropped on to a polymethylmethacrylate (PMMA)
substrate, and the HMM is adsorbed. PMMA is a useful substrate,
because photolithographic patterns can be made in them, if desired,
and the HMM placed into the tracks. In FIG. 1, the myosin is
schematically shown as myosin heads 34 projecting from the inner
surface of cylinder 14.
[0086] Once the myosin has been adhered to the inner surface of
cylinder 14, cylinder 12 may be inserted inside cylinder 14, with
both cylinders arranged concentrically around a common longitudinal
axis 36. External cylinder 14 may be mounted to a stationary
surface 38 by a bracket 40, so that the cylinder 14 remains fixed,
and inner cylinder 12 is free to rotate relative to cylinder 14,
around the central longitudinal axis 36.
[0087] In operation, a solution that contains an effective
concentration of ATP is introduced into the flow space 42 between
cylinders 12, 14, and allowed to flow through the cylinders along
their entire length. Particular concentrations of ATP (Sigma
Chemical Co., St. Louis, Mo.) that can be supplied are solutions
with an ATP concentration of 0.1 to 1000 .mu.M, for example 1
.mu.M. Greater concentrations of ATP would activate more of the
myosin molecules, and increase the speed of the motor, by rotating
cylinder 12 relative to cylinder 14. As cylinder 12 rotates,
extension 16 rotates gear 18 in the direction of arrow 22, which in
turn rotates gear 20 in the direction of arrow 24. The molecular
mechanism by which this rotation is achieved is described in more
detail in Example 2.
[0088] An alternative embodiment is shown in FIG. 2, which is
similar to that shown in FIG. 1, such that like parts have been
given like reference numbers plus 100. However, instead of inner
and outer cylinders, the motor includes inner and outer
frusto-cones 112, 114 (which for simplicity will be referred to as
"cones" 112, 114). FIG. 2 shows the molecular motor 110 in which
the outer cone 114 is mounted to a bracket 140 and surface 138.
Outer cone 114 is positioned around inner cone 112, such that the
cones taper in a complementary fashion, from a large diameter base
to a smaller diameter tip, and rotate around a common longitudinal
axis of rotation 136. A layer of actin 130 is directionally
attached to the outer surface of inner cone 112, while myosin 134
is adhered to the inner surface of outer cone 114. When supplied
with fuel, inner cone 112 rotates extension 116 and driving gear
118 in the direction of arrow 122, which in turn rotates driven
gear 120 in the direction or arrow 124.
[0089] An advantage of the embodiment of FIG. 2 is that the motor
can be assembled by inserting inner cone 112 inside outer cone 114,
with less shearing force than may be encountered when introducing
an inner cylinder into a larger outer cylinder. Since the smaller
diameter top portion of the tapering inner cone 112 can be
introduced into the larger diameter base opening of the outer
tapering cone 114, there is a greater clearance between the
inserted end and the surrounding cone than would occur with two
cylinders, each of which has a constant radius. As the inner cone
112 is progressively inserted into the outer cone 114, the minimum
desired operational clearance between the actin and myosin layers
is not reached until the two cones reach their final operational
positions. Hence the opportunity for shearing of the actin and
myosin layers, by frictional forces encountered as the motor is
assembled, is minimized.
[0090] Another alternative embodiment of the motor is shown in
FIGS. 3A and 3B, in which a hollow inner cylinder 43 is surrounded
by an outer cylinder 44. Myosin 45 (with the heads shown in random
states of conformational change in FIG. 3B) is coated on an
external surface of inner cylinder 43, while a layer of actin 46 is
directionally applied to an inner surface of outer cylinder 44.
Openings 47 are arrayed circumferentially around outer cylinder 44,
and provide passageways through the cylinder 44 and actin layer 46,
through which an ATP containing liquid can be introduced into the
space between cylinders 43 and 44. Inner cylinder 43 extends beyond
an open end of outer cylinder 44, and is mounted on a stationary
bracket 48. Myosin need not be coated on the outer surface of
cylinder 43 which extends out of cylinder 44.
[0091] In operation, a liquid containing a sufficient concentration
of ATP is introduced through passageways 47, for example through
manifold tubes (not shown) which communicate with the passageways.
In the presence of the ATP, the myosin heads 45 undergo a
conformational change to attach to actin layer 46 and move it in
the direction indicated by arrow 49. As the actin layer is moved,
its attached outer cylinder 44 is rotated around its longitudinal
axis in the direction 49, which in turn rotates propeller blades 51
that extend outwardly from the outer surface of cylinder 44. The
rotation of blades 51 can be converted to useful work, such as the
generation of power.
[0092] Although FIGS. 3A and 3B show perforations 47 in the
external cylinder 44 for introducing liquid fuel into the motor,
the liquid could similarly be introduced into the interior of the
hollow inner cylinder 43. Perforations in cylinder 43 could be
provided to direct the flow of liquid out of the inner cylinder,
and this flow would be encouraged by rotation of the surrounding
outer cylinder 44.
[0093] The molecular motor can be used in a biological organism,
such as a mammal, for example to move limbs or other body parts
that may have lost neuromuscular activity. When used to move a
limb, for example, the rotation of outer cylinder 44 can be used to
rotate a joint, for example to perform pronation or supination of
the forearm. In an assembly such as that shown in FIGS. 3A and 3B,
the inner cylinder can be fixed axially to a bone (such as the
radius or ulna, or both), and the rotating outer cylinder can be
fixed to the humerus. Activation of the motor would then rotate the
forearm relative to the upper arm. In such an example, a motor with
multiple layers would likely be required to provide sufficient
power to rotate a joint.
[0094] In yet other applications, the molecular motor may be used
in a robot, for example to rotate joints of the extremities or
trunk. Rotation of the motor can also be used in a pump to propel
fluids. Very large versions of the motor (such as multiple cylinder
embodiments about one meter wide) could also be used in automobiles
to replace conventional internal combustion motors.
Example 2
Movement of Substrates by Conformational Change of Myosin Heads
[0095] The molecular mechanism by which conformational changes of
the myosin heads move an actin coated substrate are illustrated in
FIGS. 4 and 5, which depict a conventional version of the mechanism
of muscle contraction. Although this version is illustrated for
purposes of explanation and illustration, the disclosure is not
limited to this theory, and covers any actual mechanism of muscle
contraction eventually discovered.
[0096] FIG. 4 shows a flat substrate 200 coated with a
directionally oriented layer of actin 202. In FIG. 4A, the myosin
head 204 is shown at the end of a power stroke which has moved
substrate 200. In step 1 between FIG. 4A and FIG. 4B, ATP binds to
the myosin head 204, which causes release of the myosin head 204
from the actin 202. ATP is then rapidly hydrolyzed, leaving ADP and
inorganic phosphate (P.sub.i) bound to the myosin 204, and
resulting in a conformational change (FIG. 4C) in the shape of the
myosin head which moves the head backward with respect to the
direction of desired movement of the actin. This change is followed
by the myosin binding to actin in a high energy state (FIG. 4D).
The ADP-Pi is then released, which results in another
conformational change that moves the myosin in the direction of
arrow 206, and drives the actin filament by a distance of between 4
and 10 nm in that direction.
[0097] A similar proposed mechanism applies to the movement of a
curved substrate, such as the cylinder 212 (FIG. 5) which is coated
with the layer of actin 230. FIG. 5A shows the myosin heads 234 at
the end of a power stroke. Although several myosin heads are shown
in FIG. 5 undergoing uniform movements, the myosin head which are
shown are only a subset of myosin molecules that are undergoing
similar conformational changes. Although not shown in the drawing,
many other myosin molecules are simultaneously in different stages
of the cycle.
[0098] In step 1, between FIGS. 5A and 5B, ATP binds to the myosin
heads 234, which causes release of the heads from the directionally
oriented actin layer 230. The ATP is subsequently hydrolyzed in
step 2, leaving ADP and Pi (illustrated as a black spot on the
myosin head in FIG. 5C), and resulting in a conformational change
that moves the myosin head in a direction opposite the direction of
movement of the directionally oriented actin. The myosin heads then
attach to the actin fibers (FIG. 5D), and the ADP-Pi is released,
resulting in a conformational change of the myosin that drives the
heads in the direction of arrow 236. This movement in turn moves
the actin in the direction of arrow 236 to turn the inner cylinder,
and power the motor.
Example 3
Multiple Concentric Cylinders to Increase Speed of Motor
[0099] Another embodiment of the motor is shown in FIG. 6, in which
multiple concentric cylinders are used to construct a motor that
can rotate at a higher speed than a motor having only an inner and
an outer cylinder. In the embodiment of FIG. 6, the motor includes
a solid inner cylinder 270, an intermediate cylinder 272, and an
outer cylinder 274. Although three cylinders are shown in this
example, a motor containing many more cylinders (for example 5, 10,
25, 50 or even more concentric cylinders) can similarly be
used.
[0100] The construction of the motor in FIG. 6 is analogous to that
shown in FIGS. 1-3, in that opposing surfaces of the cylinders are
coated with complementary pairs of motor proteins, such as actin
and myosin. Hence inner cylinder 270 has a layer of actin 276a
directionally coated on its external surface, while intermediate
cylinder 272 has a coating of myosin 278a on its inner surface.
Intermediate cylinder 272 also has a directional layer of actin
276b on its outer surface, and outer cylinder 274 has a coating of
myosin 278b on its inner surface.
[0101] In operation, the outer cylinder 274 is held stationary, for
example by a bracket. When an ATP-containing liquid is introduced
into the spaces between the three cylinders, the myosin on the
inner surface of outer cylinder 274 moves intermediate cylinder 272
in the direction indicated by arrow 280. Simultaneously the inner
cylinder 270 is rotated in the direction of arrow 280 by the
interaction of the complementary actin and myosin layers on the
cylinders 270, 272. Hence the rotational speed of inner cylinder
270 is the sum of the rotational speeds of intermediate cylinder
272 and inner cylinder 270. By using even more concentric cylinders
that rotate about a common longitudinal axis, the rotational speed
on the inner cylinder can be increased correspondingly.
[0102] Alternatively, in embodiments such as that shown in FIGS. 3A
and 3B in which the outer cylinder rotates relative to a stationary
inner cylinder, multiple concentric cylinders in the motor would
increase the rotational speed of the external cylinder.
[0103] FIGS. 7A and 7B illustrate a particular mode of assembly of
molecular motors that have multiple concentric nested cylinders. A
first set 281 of hollow coaxial cylinders is held in the concentric
array shown in FIG. 7A, for example by a series of internal struts,
or by affixation of an external end plate 280 (FIG. 7B) at a closed
end of the array. Set 281 includes three hollow coaxial cylinders,
consisting of an inner cylinder 282, and intermediate cylinder 284,
and an outer cylinder 286. A second set 287 of coaxial cylinders is
similarly held in a concentric array by internal struts, or
affixation of an external end plate 283 at a closed end of the
array (FIG. 7B). Set 287 also includes three cylinders, consisting
of an inner cylinder 288, an intermediate cylinder 292, and an
outer cylinder 290.
[0104] The overall outer diameter R1 of set 281 is slightly less
than an overall outer diameter R2 of set 287, and the corresponding
arrays of the alternate sets 281, 287 have staggered diameters from
the innermost to the outermost cylinder. Hence the outer diameter
of cylinder 282 is slightly less than the inner diameter of
cylinder 288. Similarly, the outer diameter of cylinder 288 is
slightly less than the inner diameter of cylinder 284, and the
outer diameter of cylinder 284 is slightly less than the inner
diameter of cylinder 292.
[0105] As illustrated schematically in FIG. 7A, actin is
directionally applied to the outer surfaces of both of the
cylinders 282, 284 (where the directional application of the actin
is illustrated by the direction of the arrows on the outer surfaces
of those cylinders). Myosin is applied to the inner surfaces of
cylinders 288, 290 and 292. Hence the motor can be assembled by
introducing set 281 into set 287, so that the cylinders of set 281
interdigitate with the cylinders of set 287. Once assembled, the
motor can be operated by introducing an ATP containing liquid into
the spaces between the cylinders.
[0106] In another embodiment (not shown), each actin bearing
surface can have raised circumferential ridges longitudinally
spaced along it. Such raised ridges would provide areas of reduced
clearance between the inner and outer cylinders, to increase the
interaction between the cylinders.
[0107] When a set number of concentric nested cylinders is included
in a molecular motor, the motor operates at a defined maximum power
and speed. However, it may be desirable to be able to vary the
power of the motor. As shown in FIG. 8, the molecular motor may be
elongated along the horizontal axis. The fuel source (e.g., an
energy molecule such as a nucleotide triphosphate, NTP) is provided
from a reservoir. In one embodiment, the fuel source is ATP.
[0108] The fuel source is selected based on the enzyme system of
the molecular motor. For example, if helicases and DNA strands are
included in a molecular motor, NTPs are provided in the reservoir
(see Waksman et al., Nat. Struct. Biol. 7:20-22, 2000 for a
discussion of helicases). In another specific, non-limiting
example, actin and myosin are included in the molecular motor, and
ATP is provided as the fuel source in the reservoir.
[0109] The fuel source (e.g. ATP) is supplied to the molecular
motor by feed lines (designated ATP.sub.1, ATP.sub.2, ATP.sub.3)
that are controlled by switches or valves (designated X on feed
lines ATP.sub.1, ATP.sub.2, ATP.sub.3) that regulate the flow rate
of fuel (e.g. ATP) through the feed lines. Power is varied by
changing the amount of available fuel along the length of the motor
using the control switches or valves.
[0110] In the embodiment illustrated, there are three feed lines
and switches, however, any number of independently controlled feed
lines and switches can be utilized. The control switches or valves
can be regulated individually, regulated in groups (e.g. 2, 3, or 4
valves that are regulated together), or can be regulated as a
single unit.
[0111] Thus, in one specific, non-limiting example, independently
controlled switches are utilized to control the flow of ATP through
the feed lines. If three switches and three ATP feed lines are
connected to the motor, switching one of the three independently
controlled switches off decreases the power to two-thirds of the
maximal power.
[0112] Another embodiment of the molecular motor, wherein power can
be regulated, is shown in FIG. 9. In this embodiment, independent
segments of a molecular motor are provided. Each segment of the
motor (shown as an independent cylinder) is attached to one end of
a feed line (designated ATP.sub.1, ATP.sub.2, ATP.sub.3 and
ATP.sub.4). The other end of each feed line is connected to a fuel
source (e.g. ATP) in a reservoir, which can deliver the fuel
through the feed lines to the segments of the molecular motor. In
the embodiment shown, the flow of ATP from the reservoir through
the feed lines is controlled by valves or switches (designated "X"
on each feed line). The motor segments are separated by impermeable
barriers (shown schematically as squares) that prevent, or
substantially inhibit, diffusion between the motor segments.
[0113] In the embodiment illustrated, four feed lines and switches
are shown, however, any number of independently controlled feed
lines and switches can be utilized. Moreover, each of the segments
can have multiple supply lines (as in FIG. 8). The control switches
or valves shown in FIG. 9 can be regulated individually, regulated
in groups (e.g. 2, 3, or 4 valves that are regulated together), or
can be regulated as a single unit.
[0114] In one specific, non-limiting example, segments of the motor
are powered independently to avoid shear. For example, if the
segments are numbered sequentially, the switch can be used to
prevent delivery of ATP to every other segment (e.g. the odd
segments) in order to run the molecular motor at half of the
maximum power. Similarly, the switch can be used to prevent
delivery of ATP to every third segment (e.g. those with a multiple
of three) to run the molecular motor at two-thirds power. The
switch can also be used to prevent delivery of ATP to two out of
three segments to run the molecular motor at one-third power.
[0115] The segments of the motor can all be of the same length, or
can have different lengths. Altering the lengths of the segments
allows variations in power. In addition, altering the numbers of
nested cylinders allows the velocity to be varied. Thus, a range of
controls is provided.
[0116] In one embodiment, a series in which the first segment has a
unit length of 1, a second segment has a unit of length 2, and
third segment has a unit of length of 4, and a fourth segment has a
unit length of 8 is provided. This series can, by binary
combinations, be programmed to have from 0 to 15 units of power.
One of skill of the art will be able to determine an appropriate
switching paradigm of segments of molecular motor of various
lengths such that any desired fraction of the maximal power of the
molecular motor can be achieved.
Example 4
Preparation of Recombinant Actin
[0117] This example describes how to prepare recombinant actin
molecules, which may also contain at least one affinity tag. Such
tags serve as a means by which to attach actin to a substrate, and
aid in the purification of recombinant actin. Purified recombinant
actin may be used for the molecular motor of the present
disclosure.
[0118] Standard molecular biology protocols are used for the
expression and purification of recombinant actin unless otherwise
stated. Such methods are described, for example, in Sambrook et al.
(Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y.,
1989), Ausubel et al. (Current Protocols in Molecular Biology,
Greene Publishing Associates and Wiley-Intersciences, 1987), and
Innis et al., (PCR Protocols, A Guide to Methods and Applications,
Innis et al. (eds.), Academic Press, Inc., San Diego, Calif.,
1990).
[0119] Partial or full-length cDNA sequences, which encode for
actin, may be ligated into bacterial expression vectors. The actin
cDNA can be from any organism including human, chicken or mouse,
and includes wild-type, mutant, and sequence variants thereof. In
addition, the actin cDNA may be from any isotype of actin,
including the .alpha., .beta., and .gamma. isoforms. Any sequence
variants used in the present disclosure will retain the ability to
interact with myosin so that the myosin can move the actin, as in
muscle. Several actin cDNA sequences are publicly available on
GenBank at: www<dot>ncbi.nlm.nih.gov. Examples include the
human (Accession No. J0068) and chicken (Accession Nos. V01507
J00805 K02172 K02257) .alpha.-actin genes, the mouse .beta.-actin
gene (Accession No. XO3672), and the human .gamma.-actin gene
(Accession Nos. X04098, K00791, M24241). It is appreciated that for
mutant or variant DNA sequences, similar systems as described below
are employed to express and produce the mutant or variant
product.
[0120] DNA sequences can be manipulated with standard procedures
such as restriction enzyme digestion, fill-in with DNA polymerase,
deletion by exonuclease, extension by terminal deoxynucleotide
transferase, ligation of synthetic or cloned DNA sequences,
site-directed sequence-alteration via single-stranded bacteriophage
intermediate, or with the use of specific oligonucleotides in
combination with PCR. The host cell, which may be transfected with
the vector of this disclosure, may be selected from the group
consisting of bacteria, yeast, fungi, plant, insect, mouse or other
animal, or human tissue cells.
[0121] The purification of recombinant fusion proteins has been
made significantly easier by the use of affinity tags that can be
genetically engineered at either the N- or C-terminus of
recombinant proteins. Such tags can be attached to actin, to aid in
its purification and subsequent attachment to a substrate (see
Example 1). Examples of affinity tags include histidine (His),
streptavidin, S-tag, and glutathione-S-transferase (GST). Other
affinity tags known to those skilled in the art may also be
used.
[0122] In general, the affinity tags are placed at the N- or
C-terminus of a protein. Vectors containing one or multiple
affinity tags are commercially available. To prepare a Tag-actin
recombinant fusion protein, vectors are constructed which contain
nucleotide sequences encoding the tag, and the actin cDNA. This
vector may be expressed in bacteria such as E. coli, and the
protein purified. The method of purification will depend on the
affinity tag attached. Typically, the bacterial lysate is applied
to a column containing a resin having high affinity for the tag on
the fusion protein. After applying the lysate and allowing the
tagged-fusion protein to bind, unbound proteins (non-tagged) are
washed away, and the fusion protein (containing the affinity tag)
is eluted.
[0123] One of the most widely used tags contains six or ten
consecutive histidine (His) residues, which has high affinity for
metal ions (such as nickel ion) which can be placed on a surface of
a curved substrate to which the actin is to be attached. A His-6 or
His-10 moiety can be attached to actin using pET vectors (Novagen,
Madison, Wis.). The His-actin fusion protein can be purified as
described in Paborsky et al. (Anal. Biochem., 234:60-65, 1996),
herein incorporated by reference. Briefly, the cell lysate is
immobilized by affinity chromatography on Ni.sup.2+-NTA-Agarose
(QIAGEN, Valencia, Calif.). After washing away unbound proteins,
for example using a buffer containing 8-50 mM imidazole, 50 mM Tris
HCl, pH 7.5, 150 mM NaCl, the bound recombinant protein is eluted
using the same buffer containing a higher concentration of
imidazole, for example 100-500 mM imidizole.
[0124] The S-tag system is based on the interaction of the 15 amino
acid S-tag peptide with the S-protein derived from pancreatic
ribonuclease A. Several vectors for generating S-tag fusion
proteins, as well as kits for the purification of S-tagged
proteins, are available from Novagen (Madison, Wis.). For example
vectors pET29a-c and pET30a-c can be used. The S-tag-actin fusion
protein may be purified by incubating the cell lystae with
S-protein agarose, which retains S-tag-actin fusion proteins. After
washing away unbound proteins, the fusion protein is released by
incubation of the agarose beads with site-specific protease, which
leaves behind the S-tag peptide. The S-tagged protein can then be
attached to the cylinder substrate, for example by the His tag
provided by this vector on the C terminus.
[0125] The affinity tag streptavidin binds with very high affinity
to biotin. Vectors for generating streptavidin-actin fusion
proteins, and methods for purifying these proteins, are described
in Santo and Cantor (Biochem. Biophys. Res. Commun. 176:571-577,
1991, herein incorporated by reference). To purify the
streptavidin-actin fusion protein, the cell lysate is applied to a
2-iminobiotin agarose column (other biotin-containing columns may
be used), and after washing away unbound proteins, the fusion
protein is eluted. Biotin can be attached to the substrate (a
surface of the cylinder, such as a glass cylinder) using the
techniques disclosed by Mazzola and Fodor, Biophys. J.
68:1653-1660, 1995, which is incorporated by reference.
[0126] The enzyme glutathione-S-transferase (GST) has high affinity
for glutathione. Plasmid expression vectors containing GST (pGEX)
are disclosed in U.S. Pat. No. 5,654,176 to Smith, herein
incorporated by reference and in Sharrocks (Gene, 138:105-8, 1994,
herein incorporated by reference). pGEX vectors are available from
Amersham Pharmacia Biotech (Piscataway, N.J.). The cell lysate is
incubated with glutathione-agarose beads and after washing, the
fusion protein is eluted, for example, with 50 mM Tris-HCl (pH 8.0)
containing 5 mM reduced glutathione. If the GST-fusion protein is
insoluble, it can be purified by affinity chromatography if the
protein is solubilized in a solubilizing agent which does not
disrupt binding to glutathione-agarose, such as 1% Triton X-100, 1%
Tween 20, 10 mM dithiothreitol or 0.03% NaDodSO.sub.4. Other
methods used to solubilize GST-fusion proteins are described by
Frangioni and Neel (Anal. Biochem. 210:179-87, 1993, herein
incorporated by reference). Glutathione fusion proteins can be
attached to an agarose covered substrate, for example a layer of
agarose on the cylindrical substrate, for example by using the
techniques disclosed in Lewis et al., Protein Expr. Pruif.
13:120-126, 1998, which is incorporated by reference.
[0127] Methods and plasmid vectors for producing fusion proteins
and intact native proteins in bacteria are described in Sambrook et
al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor,
N.Y., 1989, chapter 17, herein incorporated by reference). Such
recombinant fusion proteins may be made in large amounts, and are
easy to purify. Native proteins can be produced in bacteria by
placing a strong, regulated promoter and an efficient ribosome
binding site upstream of the cloned gene. If low levels of protein
are produced, additional steps may be taken to increase protein
production; if high levels of protein are produced, purification is
relatively easy. Suitable methods are presented in Sambrook et al.
(Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y.,
1989) and are well known in the art. Often, proteins expressed at
high levels are found in insoluble inclusion bodies. Methods for
extracting proteins from these aggregates are described by Sambrook
et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor,
N.Y., Chapter 17, 1989).
[0128] Vector systems suitable for the expression of actin fusion
genes include the pUR series of vectors (Ruther and Muller-Hill,
EMBO J. 2:1791, 1983), pEX1-3 (Stanley and Luzio, EMBO J. 3:1429,
1984) and pMR100 (Gray et al., Proc. Natl. Acad. Sci. USA 79:6598,
1982). Vectors suitable for the production of intact native
proteins include pKC30 (Shimatake and Rosenberg, Nature 292:128,
1981), pKK177-3 (Amann and Brosius, Gene 40:183, 1985) and pET-3
(Studiar and Moffatt, J. Mol. Biol. 189:113, 1986). Actin fusion
proteins may be isolated from protein gels, for use in the
molecular motor. The DNA sequence can also be transferred to other
cloning vehicles, such as other plasmids, bacteriophages, cosmids,
animal viruses and yeast artificial chromosomes (YACs) (Burke et
al., Science 236:806-812, 1987). These vectors may then be
introduced into a variety of hosts including somatic cells, and
simple or complex organisms, such as bacteria, fungi (Timberlake
and Marshall, Science 244:1313-1317, 1989), invertebrates, plants
(Gasser and Fraley, Science 244:1293, 1989), and mammals (Pursel et
al., Science 244:1281-1288, 1989), which cell or organisms are
rendered transgenic by the introduction of the heterologous actin
cDNA.
[0129] For expression in mammalian cells, the actin cDNA sequence
may be ligated to heterologous promoters, such as the simian virus
SV40 promoter, in the pSV2 vector (Mulligan and Berg, Proc. Natl.
Acad. Sci. USA 78:2072-2076, 1981), and introduced into cells, such
as monkey COS-1 cells (Gluzman, Cell 23:175-82, 1981), to achieve
transient or long-term expression. The stable integration of the
chimeric gene construct may be maintained in mammalian cells by
biochemical selection, such as neomycin (Southern and Berg, J. Mol.
Appl. Genet. 1:327-41, 1982) and mycophoenolic acid (Mulligan and
Berg, Proc. Natl. Acad. Sci. USA 78:2072-2076, 1981).
[0130] The cDNA sequence (or portions derived from it) or a mini
gene (a cDNA with an intron and its own promoter) may be introduced
into eukaryotic expression vectors by conventional techniques.
These vectors are designed to permit the transcription of the cDNA
eukaryotic cells by providing regulatory sequences that initiate
and enhance the transcription of the cDNA and ensure its proper
splicing and polyadenylation. Vectors containing the promoter and
enhancer regions of the SV40 or long terminal repeat (LTR) of the
Rous Sarcoma virus and polyadenylation and splicing signal from
SV40 are readily available (Mulligan and Berg, Proc. Natl. Acad.
Sci. USA 78:2072-2076, 1981; Gorman et al., Proc. Natl. Acad. Sci.
USA 78:6777-6781, 1982). The level of expression of the cDNA can be
manipulated with this type of vector, either by using promoters
that have different activities (for example, the baculovirus pAC373
can express cDNAs at high levels in S. frugiperda cells (Summers
and Smith, Genetically Altered Viruses and the Environment, Fields
et al. (Eds.) 22:319-328, Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, N.Y., 1985) or by using vectors that contain
promoters amenable to modulation, for example, the
glucocorticoid-responsive promoter from the mouse mammary tumor
virus (Lee et al., Nature 294:228, 1982). The expression of the
actin cDNA can be monitored in the recipient cells 24 to 72 hours
after introduction (transient expression).
[0131] In addition, some vectors contain selectable markers such as
the gpt (Mulligan and Berg, Proc. Natl. Acad. Sci. USA 78:2072-6,
1981) or neo (Southern and Berg, J. Mol. Appl. Genet. 1:327-41,
1982) bacterial genes. These selectable markers permit selection of
transfected cells that exhibit stable, long-term expression of the
vectors (and therefore the cDNA). The vectors can be maintained in
the cells as episomal, freely replicating entities by using
regulatory elements of viruses such as papilloma (Sarver et al.,
Mol. Cell. Biol. 1:486, 1981) or Epstein-Barr (Sugden et al., Mol.
Cell. Biol. 5:410, 1985). Alternatively, one can also produce cell
lines that have integrated the vector into genomic DNA. Both of
these types of cell lines produce the gene product on a continuous
basis. One can also produce cell lines that have amplified the
number of copies of the vector (and therefore of the cDNA as well)
to create cell lines that can produce high levels of the gene
product (Alt et al., J. Biol. Chem. 253:1357, 1978).
[0132] The transfer of DNA into eukaryotic, in particular human or
other mammalian cells, is now a conventional technique. The vectors
are introduced into the recipient cells as pure DNA (transfection)
by, for example, precipitation with calcium phosphate (Graham and
vander Eb, Virology 52:466, 1973) or strontium phosphate (Brash et
al., Mol. Cell. Biol. 7:2013, 1987), electroporation (Neumann et
al., EMBO J. 1:841, 1982), lipofection (Felgner et al., Proc. Natl.
Acad. Sci. USA. 84:7413-7417, 1987), DEAE dextran (McCuthan et al.,
J. Natl Cancer Inst. 41:351, 1968), microinjection (Mueller et al.,
Cell 15:579, 1978), protoplast fusion (Schafner, Proc. Natl. Acad.
Sci. USA 77:2163-7, 1980), or pellet guns (Klein et al., Nature
327:70, 1987). Alternatively, the cDNA can be introduced by
infection with virus vectors. Systems are developed that use, for
example, retroviruses (Bernstein et al., Gen. Engrg. 7:235, 1985),
adenoviruses (Ahmad et al., J. Virol. 57:267, 1986), or Herpes
virus (Spaete et al., Cell 30:295, 1982).
[0133] Using the above techniques, the expression vectors
containing the actin gene or cDNA sequence or fragments or variants
or mutants thereof can be introduced into human cells, mammalian
cells from other species or non-mammalian cells as desired. For
example, monkey COS cells (Gluzman, Cell 23:175-82, 1981) that
produce high levels of the SV40 T antigen and permit the
replication of vectors containing the SV40 origin of replication
may be used. Similarly, Chinese hamster ovary (CHO), mouse NIH 3T3
fibroblasts or human fibroblasts or lymphoblasts may be used.
[0134] The recombinant cloning vector, according to this
disclosure, then comprises the selected DNA of the DNA sequences of
this disclosure for expression in a suitable host. The DNA is
operatively linked in the vector to an expression control sequence
in the recombinant DNA molecule so that the actin polypeptide can
be expressed. The expression control sequence may be selected from
the group consisting of sequences that control the expression of
genes of prokaryotic or eukaryotic cells and their viruses and
combinations thereof. The expression control sequence may be
specifically selected from the group consisting of the lac system,
the trp system, the tac system, the trc system, major operator and
promoter regions of phage lambda, the control region of fd coat
protein, the early and late promoters of SV40, promoters derived
from polyoma, adenovirus, retrovirus, baculovirus and simian virus,
the promoter for 3-phosphoglycerate kinase, the promoters of yeast
acid phosphatase, the promoter of the yeast alpha-mating factors
and combinations thereof.
Example 5
Motor Protein Variants
[0135] Variants of the motor proteins (such as actin and myosin)
can be used instead of the native proteins, as long as the variants
retain the motor activity. DNA mutagenesis techniques may be used
to produce variant DNA molecules, and will facilitate the
production of proteins which differ in certain structural aspects
from the native protein, yet the variant proteins are clearly
derivative and maintain the essential functional characteristic of
the motor protein as defined above. Newly derived proteins may also
be selected in order to obtain variations in the characteristics of
the motor protein, as will be more fully described below. Such
derivatives include those with variations in the amino acid
sequence including minor deletions, additions and
substitutions.
[0136] While the site for introducing an amino acid sequence
variation is predetermined, the mutation per se need not be
predetermined. For example, in order to optimize the performance of
a mutation at a given site, random mutagenesis may be conducted at
a target codon or region and the expressed protein variants
screened for optimal activity. Techniques for making substitution
mutations at predetermined sites in DNA having a known sequence are
well known.
[0137] Amino acid substitutions are typically of single residues,
for example 1, 2, 3, 4 or more substitutions; insertions usually
will be on the order of about from 1 to 10 amino acid residues; and
deletions will range about from 1 to 30 residues. Substitutions,
deletions, insertions or any combination thereof may be combined to
arrive at a final construct. Obviously, the mutations that are made
in the DNA encoding the protein must not place the sequence out of
reading frame, and preferably will not create complementary regions
that could produce secondary changes in the mRNA structure.
[0138] Substitutional variants are those in which at least one
residue in the amino acid sequence has been removed and a different
residue inserted in its place. Such substitutions are generally
conservative substitutions when it is desired to finely modulate
the characteristics of the protein. Examples of such conservative
substitutions are well known, and are shown, for example, in U.S.
Pat. No. 5,928,896 and U.S. Pat. No. 5,917,019.
[0139] Substantial changes in function or immunological identity
are made by selecting substitutions that are less conservative
i.e., selecting residues that differ more significantly in their
effect on maintaining (a) the structure of the polypeptide backbone
in the area of the substitution, for example, as a sheet or helical
conformation, (b) the charge or hydrophobicity of the molecule at
the target site, or (c) the bulk of the side chain. The
substitutions which in general are expected to produce the greatest
changes in protein properties will be those in which (a) a
hydrophilic residue, e.g., seryl or threonyl, is substituted for
(or by) a hydrophobic residue, e.g., leucyl, isoleucyl,
phenylalanyl, valyl or alanyl; (b) a cysteine or proline is
substituted for (or by) any other residue; (c) a residue having an
electropositive side chain, e.g., lysyl, arginyl, or histadyl, is
substituted for (or by) an electronegative residue, e.g., glutamyl
or aspartyl; or (d) a residue having a bulky side chain, e.g.,
phenylalanine, is substituted for (or by) one not having a side
chain, e.g., glycine.
Example 6
[0140] An embodiment of a molecular motor 310 that includes annular
substrates is depicted in FIG. 10. Discs are shown as the annular
substrates in FIG. 10, but a layer of concentric rings lying in a
common plane may be substituted for each one of the discs. These
rings and ring layers are shown in detail in FIG. 13.
[0141] With reference to FIG. 10, a planar surface of a first disc
311 is secured to a base 312 so that the first disc 311 is not free
to rotate relative to the base 312. The first disc 311 may be
secured to the base 312 by any suitable manner such as by an
adhesive. A second disc 313 is secured to a drive member 314 so
that the second disc 313 is free to rotate relative to the first
disc 311. The second disc 313 may be secured to the drive member
314 by any suitable manner such as by an adhesive. The drive member
314 may include a series of gear teeth for driving a driven member
similar to that shown in FIG. 1. The first disc 311 and the second
disc 313 are axially aligned relative to each other along a central
longitudinal axis 320. The first disc 311 and the second disc 313
each define a respective orifice (depicted, for example, as element
352 in FIG. 12A or as element 372 in FIG. 12B) centered on the
central axis 320. The orifices receive a support rod 319 that is
axially aligned along the central axis 320. The support rod 319 is
secured by the base 312 so that the support rod 319 is not free to
rotate relative to the base 312. The support rod 319 is received
within the drive member 314 so that the drive member 314 and second
disc 313 remain free to rotate relative to the support rod 319.
Bushings or ball bearings (not shown) may be provided at the
surface interfaces between the support rod 319 and the drive member
314, and between the support rod 319 and the second disc 313 to
allow the relative rotation. The support rod 319 assists in
maintaining the radial alignment of the discs.
[0142] Myosin is coated on a planar surface 316 of the first disc
311 that is obverse to the disc surface secured to the base 312.
Actin is coated on a planar surface 317 of the second disc 313 that
is obverse to the disc surface secured to drive member 314. In one
embodiment (not shown) the myosin-coated surface 316 of the first
disc 311 opposes, and is sufficiently close to, the actin-coated
surface of the second disc 313 such that the myosin and actin
interact to rotate the second disc 313 relative to the first disc
311.
[0143] In another embodiment, at least one freely rotating
intermediate disc 315 is disposed between the first disc 311 and
the second disc 313. The intermediate disc 315 includes a first
planar surface that is coated with myosin 316 and an obverse second
planar surface that is coated with actin 317. The first disc 311,
intermediate disc(s) 315, and second disc 313 are arranged such
that each myosin-coated surface 316 is positioned adjacent to, or
opposes, an actin-coated surface 317. The myosin-coated surfaces
316 and the actin-coated surfaces 317 are sufficiently close to
each other so that the myosin and actin interact to rotate the
intermediate disc(s) 315 relative to each other and the first disc
311. The intermediate disc 315 located adjacent to the second disc
313 rotates the second disc 313. Although the first disc 311 is
depicted in FIG. 10 as the only disc directly affixed to a drive
member, the intermediate disc(s) 315 could also be directly coupled
to a drive member or power take-off. For example a drive belt (not
shown) could be coupled to the peripheral edge of the intermediate
disc(s) 315 or the peripheral edge of the intermediate disc(s) 315
could define a series of gear teeth (not shown). Another feature of
multiple stacked discs is that the discs could be configured to
multiply the rotational speed of the second disc 313 in a manner
analogous to the embodiment shown in FIG. 6. In other words, the
difference between the rotational velocity of the second disc 313
and the rotational velocity of the intermediate disc 315 located
the farthest distance from the second disc 313 is directly
proportional to the number of stacked discs.
[0144] During operation, a liquid containing a sufficient
concentration of ATP is introduced between the respective planar
surfaces of the discs. The myosin coated on the disc surface(s) 316
undergoes a conformation change to attach to, and move, an adjacent
actin-coated disc surface(s) 317. Movement of the actin-coated disc
surface(s) 317 moves any drive member(s) coupled to such discs.
[0145] An optional outer cylinder (not shown) encompassing the
discs may assist in directing the ATP-containing liquid to the
appropriate location. The outer cylinder may optionally include
perforations for introducing the ATP-containing liquid into the
cylinder's interior. Alternatively, the ATP-containing liquid could
be introduced via openings (not shown) provided in the central
support rod 319. The discs may be constructed to facilitate the
flow of the ATP-containing liquid.
[0146] For example, FIG. 12A shows a representative disc embodiment
350 that includes voids or perforations 354 arranged
circumferentially around the disc orifice 352. The voids 354 may be
designed such that they have a wide opening at the peripheral edge
of the disc 350 tapering down to a closed end at the edge of the
disc orifice 352. Such a design results in propeller-shaped disc
blades 351 arranged circumferentially around the disc orifice 352.
Each propeller-shaped disc blade may have a leading edge 355 that
is swept back or arcuate in a direction corresponding to the
rotation direction of the disc 350. Actin may be directionally
applied to a surface of the disc blades 351 as represented by
arrows 353. Of course, myosin may be coated on the surface rather
than actin. As the disc 350 rotates clockwise, the ATP-containing
liquid ("ATP" in FIGS. 12A and 12B) is swept in along the leading
edges 355 of the disc blades 351 so that it contacts the
actin-coated surfaces. The ATP-containing liquid would be drawn
towards the center of the disc 350. The support rod 319 could be
provided with openings (not shown) for receiving the waste ATP
liquid and discharging it from the motor. Adjacent discs 350 with
the propeller configuration should be designed so that there is
overlap at all operating times between at least a portion of the
adjacent disc blade 351 surfaces and, thus, contact between the
motor proteins. For example, the voids 354 could be smaller than
the disc blades 351 or the voids 354 could have a different
geometric shape relative to the geometric shape of the disc blades
351.
[0147] FIG. 12B shows another representative disc embodiment 370
that includes grooves or indentations 371 formed on a surface of
the disc 370 that is coated with myosin molecules 373. The grooves
371 could extend from the peripheral edge of the disc 370 to the
edge of the disc orifice 372. The grooves 371 are swept back or
arcuate to facilitate flow of the ATP-containing liquid across the
surface of the disc 370 and towards the center of the disc 370 as
the disc 370 rotates clockwise. The support rod 319 could be
provided with openings (not shown) for receiving the waste ATP
liquid and discharging it from the motor. The grooves 371 are shown
in FIG. 12B as continuous grooves but could be discontinuous
grooves.
[0148] As mentioned above, the discs depicted in FIG. 10 could be
replaced by rings as illustrated in FIG. 13. At least two
concentric rings 410 lie in a common plane around a central orifice
412 to form a ring layer 413. The rings 410 may be rigid or
flexible. A stationary central support rod 426 is received within
the central orifice 412. Each ring layer 413 includes a central
ring 427 that defines an annular inner surface 428 that is fixedly
secured to the surface of the central support rod 426. The central
support rod 426 and the central rings 427 may form an integral
member. One end of the central support rod 426 is fixedly secured
to a base 416. The common plane of each ring layer 413 is
transverse to a longitudinal axis 425. The ring layers 413 are
located axially adjacent each other along the longitudinal axis
425. With reference to FIG. 13, "axially" or "axial" denotes a
direction parallel to the longitudinal axis 425 and "radially" or
"radial" denotes a direction transverse to the longitudinal axis
425. A first planar surface 414 of the ring 410 is coated with a
motor protein such as, for example, myosin. An obverse second
planar surface 415 of the ring 410 is coated with a complementary
motor protein such as, for example, actin. A gap 411 is provided
between adjacent rings 410. The support rod 426 and concentric ring
arrangement assist in maintaining the radial alignment of the rings
410. Each ring 410 (except central rings 427) is free to rotate
relative to any other ring 410 and relative to the stationary
support rod 426.
[0149] At least two, more particularly at least three, ring layers
413 are disposed adjacent to each other, for example, in a stacked
configuration, such that the myosin-coated surfaces 414 oppose the
actin-coated surfaces 415. A base 416 defining a surface 417 is
provided adjacent to a bottom ring layer. Ball bearings or similar
friction reducing materials may be provided on the surface 417.
Drive member(s) (not shown) may be coupled to any of the rotating
rings 410 in a manner similar to those described above in
connection with the other embodiments.
[0150] The location of each gap 411 in a given ring layer is
radially offset from the location of each gap 411 in adjacent ring
layers. Consequently, each individual ring 410 can assist in
directly driving or powering two rings 410 in the adjacent ring
layers 413. Such cooperation between the rings is illustrated by
examining a given ring 420 in a given ring layer 418. Rotation of
ring 420 will drive both rings 422 and 421 in adjacent ring layer
419 since the myosin-coated surface 414 of ring 420 contacts a
portion of the actin-coated surface 415 of ring 422 and a portion
of the actin-coated surface 415 of ring 421. Ring 422 in ring layer
419 in turn drives ring 423 in ring layer 418. Each central ring
(e.g., ring 427) is stationary. Thus, the myosin-coated surface 414
of central ring 427 drives the actin-coated surface 415 of the
innermost freely rotating ring 429 in adjacent ring layer 419.
Similarly, the actin-coated surface 415 of central ring 427 drives
the myosin-coated surface 414 of ring 430 in the other adjacent
layer. In this arrangement, the outer rings will have greater
rotational speeds than the inner rings.
[0151] Opposing curved surfaces (e.g., surface 424) between
adjacent rings (e.g., rings 420 and 423) in the same layer may also
be coated with complementary motor proteins so that all rings
surfaces can contribute to the drive power.
[0152] Similar to the above-described embodiment, a liquid
containing a sufficient concentration of ATP is introduced between
the respective planar surfaces of the ring layers. The myosin
coated on the surface(s) 414 undergoes a conformation change to
attach to, and move, an adjacent actin-coated surface 415. The
drive cooperation among the individual rings permits 410
substantial radial narrowing of the planar surfaces 414, 415 of the
rings 410. The decreased radial width means that substantially
uniform rotational velocities are present across the planar
surfaces 414, 415 of each ring 410. Consequently, the motor protein
interaction across the planar surfaces 414, 415 can occur at
optimum uniform speeds, thus improving the efficiency of the
motor.
[0153] An optional outer cylinder (not shown) encompassing the ring
layers 413 may assist in directing the ATP-containing liquid to the
appropriate location. The outer cylinder may optionally include
perforations for introducing the ATP-containing liquid into the
cylinder's interior. Alternatively, the ATP-containing liquid could
be introduced via openings (not shown) provided in the central
support rod 426. The planar surfaces 414, 415 of the rings 410 may
be provided with grooves as described in connection with FIG. 12B
to facilitate the flow of the ATP-containing liquid. The outermost
peripheral rings 410 could be affixed to the outer cylinder and,
thus, the outer cylinder could be coupled to a drive member (not
shown) in a manner similar to that shown in FIG. 1.
[0154] FIG. 11 illustrates another molecular motor 330 embodiment
that includes interdigitated discs. A stationary hollow cylinder
336 is supported on a base 335 and defines an internal void 339
that receives a drive shaft 333. A mounting element 337 is received
within a cavity 338 defined in the base 335. The mounting element
337 rotatably secures the drive shaft 333 to the base 335. A drive
member 334 is coupled to the drive shaft 333 in any suitable
manner. The drive member 334 may define gear teeth, support a drive
belt, or be configured in any similar manner to provide useful
work.
[0155] At least one outer disc 332 is mounted onto the inner
surface of the stationary cylinder 336. Planar surfaces 340 of the
outer disc(s) 332 may be coated with myosin or, alternatively,
actin. The outer disc(s) 332 defines a central orifice receiving
the drive shaft 333. The central orifice is designed to allow the
drive shaft 333 to rotate freely relative to the stationary outer
disc(s) 332. For example, the circumference of the central orifice
may be sufficiently greater than the circumference of the drive
shaft 333 so that no contact can occur or, alternatively, bushings,
ball bearings or similar devices may be located at the orifice
edge/drive shaft edge interface.
[0156] At least one inner disc 331 is also disposed in the void
339. Planar surfaces 341 of the inner disc(s) 331 may be coated
with actin or, alternatively, myosin. If the surfaces 341 of the
inner disc(s) are coated with actin, then the surfaces 340 of the
outer disc(s) 332 should be coated with myosin. The inner disc(s)
331 and outer discs(s) 332 are arranged in an alternating pattern,
and sufficiently close to each other, so that the actin and myosin
can interact together in the presence of ATP. The inner disc 331
defines a central orifice as shown, for example, in FIGS. 12A and
12B. The drive shaft 333 is received in the central orifice and is
affixed to the inner disc 331 at the edges of the central
orifice.
[0157] During operation, a liquid containing a sufficient
concentration of ATP is introduced between the respective planar
surfaces of the discs. The actin and myosin interact with each
other as described above. Movement of the actin layer attached to
the inner disc(s) 331 results in rotation of the drive shaft 333
and drive member 334 relative to the stationary cylinder 336 and
stationary outer disc(s) 332.
[0158] A variant (not shown) of the motor 330 illustrated in FIG.
11 could include an outer cylinder and attached outer disc(s) that
could rotate relative to a stationary inner support rod and
attached inner disc(s). The rotatable outer cylinder would be
coupled to the drive member.
[0159] Variants of the above-described cylinder or cone embodiments
are shown in FIGS. 14 and 15. In each of these variants, at least
one continuous loop of a flexible substrate follows an elongated
cylindrical, oblong, elliptical, serpentine or similar multiple
turning radii rotation path. The flexible substrate can be, for
example, a tape or thread, made from a compliant material such as a
fibrous material. The continuous loop is supported by, and/or the
rotation path is directed by, at least two rotation loci members
such as another nested continuous loop (that, in turn, includes at
least two rotation loci), cylinders or stanchions. One of the
rotation loci members defines a surface that drives the continuous
loop as detailed below. The rotation loci members are located at
internal and/or external turning radii defined by the continuous
loop.
[0160] With reference to FIG. 14, a molecular motor 440 is shown
that includes a first cylinder 445 and a second cylinder 444
disposed, respectively, within a first internal radius 453 and a
second internal radius 454 defined by a first flexible loop
substrate 441. The first flexible loop substrate 441 defines an
inner surface 448 and an outer surface 449. The inner surface 448
is in contact with, and supported by, peripheral surface 452 of
first cylinder 445 and peripheral surface 451 of second cylinder
444. The first loop substrate 441 is disposed within a first
internal radius 455 of a second flexible loop substrate 442. A
third cylinder 443 is disposed within a second internal radius 456
of the second loop substrate 442. The second loop substrate 442
defines an inner surface 446 and an outer surface 447. The inner
surface 446 is in contact with, and supported by, peripheral
surface 450 of third cylinder 443 and the outer surface 449 of the
first loop substrate 441. At least one of the second and third
cylinders 444, 443 are rotatable and may be coupled to a drive
member (not shown) in a manner similar to that depicted, for
example, in FIG. 1. First cylinder 445 is stationary. At least one
of the first, second and third cylinders 445, 444, 443 also may be
extended and coupled to a base member (not shown) for supporting
the molecular motor 440. A drive member such as a belt (not shown)
may also be engaged with the outer surface 447 of the second loop
substrate 442.
[0161] The peripheral surface 452 of the first cylinder 445 is
coated with a motor protein (e.g., myosin) and the inner surface
448 of the first loop substrate 441 is coated with a complementary
motor protein (e.g., directionally applied actin). The outer
surface 449 of the first loop substrate 441 also is coated with a
motor protein (e.g., directionally applied actin) and the inner
surface 446 of the second loop substrate 442 is coated with a
complementary motor protein (e.g., myosin). The actin/myosin
interaction upon exposure to ATP moves the first loop substrate 441
relative to the second loop substrate 442. Movement of the first
loop substrate 441 and/or second loop substrate 442 rotates at
least one of the second or third cylinders 444, 443. Second loop
substrate 442 may be provided with perforations (not shown) for
introducing an ATP-containing liquid between the inner surface 446
of the second loop substrate 442 and the outer surface 449 of the
first loop substrate 441.
[0162] Additional nested loop substrates may be provided to
increase the rotational velocity of the outer loop substrate.
Increasing the width of the loop substrates can increase the power
of the molecular motor 440.
[0163] With reference to FIG. 15, a molecular motor 470 is shown
that includes a cylinder 472 disposed within a first internal
radius 478 defined by a flexible loop substrate 471. A plurality of
stationary posts or stanchions 473 are disposed within second radii
479 defined by the loop substrate 471. According to particular
embodiments, there are at least three posts 473 so that the loop
substrate follows a serpentine path. Each post 473 defines an outer
surface 477. The loop substrate 471 defines an inner surface 474
and an outer surface 475. The inner surface 474 is in contact with,
and supported by, peripheral surface 476 of cylinder 472 and the
outer surfaces 477 of the posts 473. The cylinder 472 may be
stationary or rotatable. If the cylinder 472 is rotatable, it may
be coupled to a drive member (not shown). A drive member (not
shown) may also be engaged with the loop substrate 471. For
example, the edges of the loop substrate 471 may define gear teeth
(not shown) for engaging with a driven member (not shown). Such
gear teeth may also assist in supporting the molecular motor
470.
[0164] The outer surface 477 of each stationary post 473 is coated
with a motor protein (e.g., myosin). The inner surface 474 and the
outer surface 475 of the loop substrate 471 are coated with a
complementary motor protein (e.g., directionally applied actin).
The actin/myosin interaction upon exposure to ATP moves the loop
substrate 471 relative to the posts 473 and, thus, moves any
coupled drive members. The loop substrate 471 may be provided with
perforations (not shown) for introducing an ATP-containing liquid
between the surfaces 474, 475 of the loop substrate 471 and the
outer surfaces 477 of the posts 473. Increasing the width of the
loop substrate 471, the contact length between the outer surfaces
477 of the posts 473 and the surfaces 474, 475 of the loop
substrate 471, and/or increasing the number of posts 473 can
increase the power of the molecular motor 470.
[0165] The motor protein-coated loop substrate shown in the
embodiments of FIGS. 14 and 15 can be made by passing the loop
substrate through a bath(s) that includes the desired motor
protein. The motor protein-coated loop substrate may be placed
around the support cylinders. The tension of each individual loop
then may be adjusted accordingly.
[0166] In view of the many possible embodiments to which the
principles of our disclosure may be applied, it should be
recognized that the illustrated embodiment is only a particular
example of the disclosure and should not be taken as a limitation
on the scope of the disclosure. Rather, the scope of the disclosure
is defined by the following claims.
* * * * *